Cargando…
Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial
The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster-randomized trial showed that a mobile health (mHealth)-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach reduced the risk of adverse events in atrial fibrillation (AF) patient...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017580/ https://www.ncbi.nlm.nih.gov/pubmed/36630000 http://dx.doi.org/10.1007/s11739-022-03188-2 |
_version_ | 1784907621284708352 |
---|---|
author | Guo, Yutao Corica, Bernadette Romiti, Giulio Francesco Proietti, Marco Zhang, Hui Lip, Gregory Y. H. |
author_facet | Guo, Yutao Corica, Bernadette Romiti, Giulio Francesco Proietti, Marco Zhang, Hui Lip, Gregory Y. H. |
author_sort | Guo, Yutao |
collection | PubMed |
description | The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster-randomized trial showed that a mobile health (mHealth)-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach reduced the risk of adverse events in atrial fibrillation (AF) patients. Whether this benefit can be applied to both males and females is unclear, especially given the suboptimal management and poorer cardiovascular outcomes in females with AF. In this post-hoc analysis, we performed a sex-stratified analysis of the mAFA-II trial. Between June 2018 and August 2019, adult AF patients were enrolled across 40 centers in China. The primary outcome was the composite of stroke, thromboembolism, all-cause death, and re-hospitalization. The effect of mAFA intervention according to sex was evaluated through adjusted Cox-regression models. Among the 3,324 patients enrolled in the trial, 2,062 (62.0%) patients were males (mean age: 67.5 ± 14.3 years; 1,021 allocated to mAFA intervention) and 1,262 (38.0%) were females (mean age: 70.2 ± 13.0; 625 allocated to mAFA intervention). A significant risk reduction of the primary composite outcome in patients allocated to mAFA intervention was observed in both males (adjusted hazard ratio [aHR] and 95% confidence interval [CI] 0.30 [0.17–0.52]) and females (aHR [95%CI] 0.50 [0.27–0.92]), without statistically significant interaction (p = 0.225). Sex-based interactions were observed for other secondary outcomes, including all-cause death (p = 0.026) and bleeding events (p = 0.032). A mHealth-technology implemented ABC pathway was similarly effective in reducing the risk of adverse clinical events both in male and female patients. Secondary outcomes showed greater benefits of mAFA intervention in men. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-03188-2. |
format | Online Article Text |
id | pubmed-10017580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-100175802023-03-17 Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial Guo, Yutao Corica, Bernadette Romiti, Giulio Francesco Proietti, Marco Zhang, Hui Lip, Gregory Y. H. Intern Emerg Med Im - Original The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster-randomized trial showed that a mobile health (mHealth)-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach reduced the risk of adverse events in atrial fibrillation (AF) patients. Whether this benefit can be applied to both males and females is unclear, especially given the suboptimal management and poorer cardiovascular outcomes in females with AF. In this post-hoc analysis, we performed a sex-stratified analysis of the mAFA-II trial. Between June 2018 and August 2019, adult AF patients were enrolled across 40 centers in China. The primary outcome was the composite of stroke, thromboembolism, all-cause death, and re-hospitalization. The effect of mAFA intervention according to sex was evaluated through adjusted Cox-regression models. Among the 3,324 patients enrolled in the trial, 2,062 (62.0%) patients were males (mean age: 67.5 ± 14.3 years; 1,021 allocated to mAFA intervention) and 1,262 (38.0%) were females (mean age: 70.2 ± 13.0; 625 allocated to mAFA intervention). A significant risk reduction of the primary composite outcome in patients allocated to mAFA intervention was observed in both males (adjusted hazard ratio [aHR] and 95% confidence interval [CI] 0.30 [0.17–0.52]) and females (aHR [95%CI] 0.50 [0.27–0.92]), without statistically significant interaction (p = 0.225). Sex-based interactions were observed for other secondary outcomes, including all-cause death (p = 0.026) and bleeding events (p = 0.032). A mHealth-technology implemented ABC pathway was similarly effective in reducing the risk of adverse clinical events both in male and female patients. Secondary outcomes showed greater benefits of mAFA intervention in men. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-03188-2. Springer International Publishing 2023-01-11 2023 /pmc/articles/PMC10017580/ /pubmed/36630000 http://dx.doi.org/10.1007/s11739-022-03188-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Im - Original Guo, Yutao Corica, Bernadette Romiti, Giulio Francesco Proietti, Marco Zhang, Hui Lip, Gregory Y. H. Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial |
title | Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial |
title_full | Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial |
title_fullStr | Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial |
title_full_unstemmed | Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial |
title_short | Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial |
title_sort | efficacy of mobile health-technology integrated care based on the ‘atrial fibrillation better care’ (abc) pathway in relation to sex: a report from the mafa-ii randomized clinical trial |
topic | Im - Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017580/ https://www.ncbi.nlm.nih.gov/pubmed/36630000 http://dx.doi.org/10.1007/s11739-022-03188-2 |
work_keys_str_mv | AT guoyutao efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial AT coricabernadette efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial AT romitigiuliofrancesco efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial AT proiettimarco efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial AT zhanghui efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial AT lipgregoryyh efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial AT efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial |